MedTrace Logo

VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management

NCT00970892 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2009-09-03

No results posted yet for this study

Summary

The investigators aimed to use pharmacogenetic information in clinical practise which may lead to rapid, efficient, and safe warfarin dosing in this observational prospective study. In this context, the investigators plan to develop an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from the Turkish study population. This study is unique not only investigating clinical factors, demographic variables, CYP2C9, and VKORC1 gene variations which contribute to the variability among patients in dose requirements for warfarin but also including thrombogenic single nucleotide polymorphisms (SNP) in the same patient population. Thus, warfarin would be a good example by being the first cardiovascular drug for pharmacogenetic guided "personalized medicine" applications.

Conditions

  • Atrial Fibrillation
  • Cardiac Thrombus
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Heart Valve Replacement (Mechanical or Biological With AF)
  • Cardiomyopathy (Ischemic or Dilated)
  • Peripheral Vascular Disease

Interventions

DRUG

Warfarin dose titration

Dosage

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Principal Investigators

  • Nejat Akar, Prof · Ankara University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970892 on ClinicalTrials.gov